ArticleClinical and experimental medicine2025
The dual burden of tuberculosis and diabetes mellitus: an epidemiological correlation.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of the efficacy of retroperitoneoscopic debridement for lumbar tuberculosis: a retrospective study and preliminary results.International orthopaedics · 2026Article
- From silos to synergy: assessing tuberculosis basic management units readiness for integrated diabetes mellitus care across different districts of Pakistan.Primary health care research & development · 2026Article
- Effects of aminoglycosides on macrophage viability and antimicrobial function under high-glucose exposure.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the association between diabetes mellitus and tuberculosis (TB) in a cohort of 200TB-positive patients, stratified by gender, age, treatment regimen, and comorbidities, including diabetes, acute gastroenteritis, and hypertension, compared to TB patients without additional complications. Clinical parameters-Random Blood Sugar (RBS), C-reactive protein (CRP), and Erythrocyte Sedimentation Rate (ESR)-were assessed at baseline and after four months of anti-TB therapy. The results showed no significant changes in mean RBS or CRP levels post-treatment, but a notable reduction in mean ESR was observed. Age and gender had minimal impact on therapeutic outcomes for RBS, CRP, or ESR, though females exhibited higher ESR values than males. Treatment regimens, whether Myrin P Forte alone or combined with streptomycin, did not significantly alter clinical parameters. However, CRP levels improved in TB patients with comorbidities, such as diabetes, hypertension, or gastroenteritis. A significant prevalence of diabetes (21.42%) was found among TB patients, with higher rates in females and those over 50 years. These findings highlight a notable association between diabetes and TB. However, the minimal effect of anti-TB therapy on clinical parameters suggests that ESR and CRP may not be reliable prognostic markers for TB. The study underscores the need for further large-scale case-control studies and molecular research to better understand the relationship between diabetes and TB, particularly given the high prevalence of diabetes among TB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.